Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Palisade Bio Inc (PALI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: PALI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.67
1 Year Target Price $10.67
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.24% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.76M USD | Price to earnings Ratio - | 1Y Target Price 10.67 |
Price to earnings Ratio - | 1Y Target Price 10.67 | ||
Volume (30-day avg) 3 | Beta 1.34 | 52 Weeks Range 0.60 - 4.89 | Updated Date 07/12/2025 |
52 Weeks Range 0.60 - 4.89 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.07 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -80.94% | Return on Equity (TTM) -170.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -3408279 | Price to Sales(TTM) 14.03 |
Enterprise Value -3408279 | Price to Sales(TTM) 14.03 | ||
Enterprise Value to Revenue 234.89 | Enterprise Value to EBITDA 0.57 | Shares Outstanding 4795650 | Shares Floating 4301790 |
Shares Outstanding 4795650 | Shares Floating 4301790 | ||
Percent Insiders 0.46 | Percent Institutions 5.43 |
Upturn AI SWOT
Palisade Bio Inc
Company Overview
History and Background
Palisade Bio, Inc. (formerly Seneca Biopharma, Inc.), founded in 2008, is a biopharmaceutical company focused on developing novel therapeutics for indications impacting the gastrointestinal (GI) system.
Core Business Areas
- Lead Asset Development: Development of LB1148, a novel oral formulation of a protease inhibitor, for accelerating the return of bowel function following surgery.
Leadership and Structure
The leadership team is led by Darlene M. Conley, M.D., as Chief Executive Officer. The organizational structure comprises research and development, clinical operations, and corporate administration departments.
Top Products and Market Share
Key Offerings
- LB1148: LB1148 is Palisade Bio's lead product candidate designed to neutralize digestive enzymes, potentially speeding up the return of bowel function post-surgery. Market share is currently 0% as it is in clinical development. Competitors include current standard of care like supportive care and potentially future competing therapies targeting post-operative ileus (POI).
Market Dynamics
Industry Overview
The pharmaceutical industry is continuously innovating in drug development and clinical applications. There is a demand for better treatments for GI-related conditions and post-operative care.
Positioning
Palisade Bio is positioned to address a significant unmet need in accelerating the return of bowel function post-surgery. Its competitive advantage lies in the novel mechanism of action of LB1148.
Total Addressable Market (TAM)
The TAM for therapies addressing post-operative ileus is estimated to be in the hundreds of millions of dollars annually. Palisade Bio is aiming to capture a significant portion of this market with LB1148.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (LB1148)
- Experienced management team
- Targeting a significant unmet medical need
Weaknesses
- Reliance on a single lead product candidate
- Limited financial resources
- Clinical and regulatory risks
Opportunities
- Successful clinical trials and regulatory approval of LB1148
- Partnerships with larger pharmaceutical companies
- Expansion into additional GI indications
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
Competitors and Market Share
Key Competitors
Competitive Landscape
Palisade Bio's competitive advantage lies in LB1148's novel mechanism. The competitive landscape includes supportive care methods, other pharmaceutical interventions targeting ileus or bowel obstruction.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal as the company is focused on drug development and has not yet launched a commercial product.
Future Projections: Future growth depends on the successful development and commercialization of LB1148 and potential expansion into other GI indications.
Recent Initiatives: Recent initiatives include advancing LB1148 through clinical trials and seeking strategic partnerships.
Summary
Palisade Bio is a biopharmaceutical company with a promising lead product candidate, LB1148, targeting a significant unmet need in post-operative ileus. Its success hinges on the successful completion of clinical trials and securing regulatory approval. The company faces inherent risks associated with drug development, including potential clinical trial failures and regulatory hurdles. Palisade Bio needs to closely manage its cash flow and explore opportunities for partnerships to mitigate financial risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Palisade Bio Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2006-12-20 | CEO, CFO & Director Mr. J. D. Finley | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.palisadebio.com |
Full time employees 8 | Website https://www.palisadebio.com | ||
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.